Figures & data
Figure 1. Major route steps to obtain 2,4-diaminopyrimidine derivatives 1–5. Chemical structures are shown in the lower panel.
![Figure 1. Major route steps to obtain 2,4-diaminopyrimidine derivatives 1–5. Chemical structures are shown in the lower panel.](/cms/asset/22b2a636-ae96-4a23-8661-140180739ce4/ienz_a_1651311_f0001_b.jpg)
Figure 2. Cloning, expression, purification, and kinetic characterization results for LcPTR1. (A) Cloning steps to insert LcPTR1 gene into pETM11 expression vector monitored by 1% agarose gel. A1: (1) Marker 1 kb DNA Ladder, A1: (2) PCR amplification product with base pairs (bp) equivalent to LcPTR1 gene; A2: (1) Tridye 100pb ladder (NEB); A2: (2) Product of PCR reaction employing E. coli CFU resulting from the transformation protocol. (B) Expression and purification of LcPTR1. SDS/page 12%. (B1) Protein expression profile of LcPTR1 in E. coli BL21 (DE3). After expression induction at 25 °C (18 h), in the presence of different IPTG concentrations (0.05, 0.5, and 1.0 mM). NI: the absence of IPTG; P: pellet: S: supernatant; MM: LMW-SDS GE molecular weight standard (kDa). B2: (1) molecular weight standard (kDa); (2) purification supernatant; (3) fraction 20 mM imidazole; (4–6) 50 mM imidazole; (7–9) 500 mM imidazole. (10) LcPTR1 after cleavage. (C) Activity of LcPTR1 in different pH ranges. Values represent median and interquartile range of % activity when compared to the highest median of activity obtained, at pH 4, 7 (N = 3). (D) Apparent Km determination for recombinant LcPTR1.
![Figure 2. Cloning, expression, purification, and kinetic characterization results for LcPTR1. (A) Cloning steps to insert LcPTR1 gene into pETM11 expression vector monitored by 1% agarose gel. A1: (1) Marker 1 kb DNA Ladder, A1: (2) PCR amplification product with base pairs (bp) equivalent to LcPTR1 gene; A2: (1) Tridye 100pb ladder (NEB); A2: (2) Product of PCR reaction employing E. coli CFU resulting from the transformation protocol. (B) Expression and purification of LcPTR1. SDS/page 12%. (B1) Protein expression profile of LcPTR1 in E. coli BL21 (DE3). After expression induction at 25 °C (18 h), in the presence of different IPTG concentrations (0.05, 0.5, and 1.0 mM). NI: the absence of IPTG; P: pellet: S: supernatant; MM: LMW-SDS GE molecular weight standard (kDa). B2: (1) molecular weight standard (kDa); (2) purification supernatant; (3) fraction 20 mM imidazole; (4–6) 50 mM imidazole; (7–9) 500 mM imidazole. (10) LcPTR1 after cleavage. (C) Activity of LcPTR1 in different pH ranges. Values represent median and interquartile range of % activity when compared to the highest median of activity obtained, at pH 4, 7 (N = 3). (D) Apparent Km determination for recombinant LcPTR1.](/cms/asset/4c6a6ba2-fe23-4ff2-a277-f8c2dddb8748/ienz_a_1651311_f0002_c.jpg)
Figure 3. Cloning, expression, purification and kinetic characterization results for LcDHFR-TS. (A) Cloning steps of the LcDHFR-TS gene in the pET28a vector, monitored by 1% agarose gel. A1, A2: (1) Marker 1 kb DNA Ladder; A1: (2) Product of the amplification reaction of the LcDHFR-TS gene from the genomic DNA; A2: (2) Product of PCR reaction with primer T7 employing CFU from the transformation protocol. (B) Expression and purification of LcDHFR-TS. Gel SDS-page 12%. (1) Molecular weight standard; (2–3) insoluble and soluble fraction of the lysate; (4–5) contaminants eluted in low imidazole concentration; (6–7) Wash with buffer containing 500 mM imidazole; (8–10) Column eluate with imidazole-free buffer after application of the dialyzed material and incubated with thrombin. (C) Activity of LcDHFR-TS in different pH ranges. Values represent median and interquartile range of % activity when compared to the highest median of activity obtained, at pH 7.0 (N = 3). (D) Apparent Km determination for LcDHFR-TS.
![Figure 3. Cloning, expression, purification and kinetic characterization results for LcDHFR-TS. (A) Cloning steps of the LcDHFR-TS gene in the pET28a vector, monitored by 1% agarose gel. A1, A2: (1) Marker 1 kb DNA Ladder; A1: (2) Product of the amplification reaction of the LcDHFR-TS gene from the genomic DNA; A2: (2) Product of PCR reaction with primer T7 employing CFU from the transformation protocol. (B) Expression and purification of LcDHFR-TS. Gel SDS-page 12%. (1) Molecular weight standard; (2–3) insoluble and soluble fraction of the lysate; (4–5) contaminants eluted in low imidazole concentration; (6–7) Wash with buffer containing 500 mM imidazole; (8–10) Column eluate with imidazole-free buffer after application of the dialyzed material and incubated with thrombin. (C) Activity of LcDHFR-TS in different pH ranges. Values represent median and interquartile range of % activity when compared to the highest median of activity obtained, at pH 7.0 (N = 3). (D) Apparent Km determination for LcDHFR-TS.](/cms/asset/70c1e6ad-7d32-490c-b618-fb91b4dbad5e/ienz_a_1651311_f0003_b.jpg)
Figure 4. Kinetic inhibition assays results for LcPTR1. (A) Single concentration (50 μM) inhibition assay. (B) Dose-response curves for compounds 1–5 against LcPTR1. IC50 values calculated by non-linear regression in GraphPad Prism® 5.0 software. (C) Effect of compound 1 over NADPH and BPT kinetic constants (Kmapp and Vmaxapp). *Statistical difference of results were considered when p < .05 (Kruskal–Wallis ANOVA). (D) Effect of compound 5 over NADPH and BPT kinetic constants (Kmapp and Vmaxapp) *Statistical difference of results were considered when p < .05 (Kruskal–Wallis ANOVA).
![Figure 4. Kinetic inhibition assays results for LcPTR1. (A) Single concentration (50 μM) inhibition assay. (B) Dose-response curves for compounds 1–5 against LcPTR1. IC50 values calculated by non-linear regression in GraphPad Prism® 5.0 software. (C) Effect of compound 1 over NADPH and BPT kinetic constants (Kmapp and Vmaxapp). *Statistical difference of results were considered when p < .05 (Kruskal–Wallis ANOVA). (D) Effect of compound 5 over NADPH and BPT kinetic constants (Kmapp and Vmaxapp) *Statistical difference of results were considered when p < .05 (Kruskal–Wallis ANOVA).](/cms/asset/edfce12e-aad8-479b-a756-5153d4ab8bab/ienz_a_1651311_f0004_b.jpg)
Figure 5. Kinetic inhibition assays results for LcDHFR-TS. (A) Inhibition profile against in 50 μM inhibitor single concentration assay. (B) Dose-response curves for compounds 1–3 against LcDHFR-TS. IC50 values calculated by non-linear regression in GraphPad Prism® 5.0 software. (C) Effect of compound 1 over NADPH and DHF kinetic constants (Kmapp and Vmaxapp). *Statistical difference of results were considered when p < .05 (Kruskal–Wallis ANOVA).
![Figure 5. Kinetic inhibition assays results for LcDHFR-TS. (A) Inhibition profile against in 50 μM inhibitor single concentration assay. (B) Dose-response curves for compounds 1–3 against LcDHFR-TS. IC50 values calculated by non-linear regression in GraphPad Prism® 5.0 software. (C) Effect of compound 1 over NADPH and DHF kinetic constants (Kmapp and Vmaxapp). *Statistical difference of results were considered when p < .05 (Kruskal–Wallis ANOVA).](/cms/asset/458dd23c-45bd-45fc-877f-3453391a2b3b/ienz_a_1651311_f0005_b.jpg)
Table 1. Selectivity ratio for the 2,4-diaminopyrimidine derivates active against LcDHFR-TS and LcPTR1.